anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A system for determining relative operational performance in a clinical trial may include a processor, a data comparator and visualizer, and a graphical user interface. The processor filters received clinical data into multiple metric criteria to generate multiple metric data sets and filters each metric data set into a respective industry data set and a respective candidate data set. The processor then calculates statistical measures for each industry data set and candidate data set and transforms each industry data set and candidate data set based on each data set&#39;s respective statistical measures. The data comparator and visualizer compares each transformed candidate data set to the transformed industry data set for the respective metric criterion to determine a candidate percentile for each metric criterion. The graphical user interface displays the candidate percentiles for the metric criteria. A method for determining relative operational performance in a clinical trial is also described.
PURPOSE:To provide the subject new compound useful for preventing and improving dysuria such as pollakiuria or incontinence of urine. CONSTITUTION:A compound of formula I (R&lt;1&gt; and R&lt;2&gt; are each H or a lower aliphatic hydrocarbon which may be substituted; R&lt;3&gt; is H or an aryl which may be substituted; R&lt;4&gt; is an aryl which may be substituted), e.g. hydrochloride of N-tert-butyl-2,3-diphenyl-2-cyclopentene-1-amine. The compound of formula I can be obtained by reacting a compound of formula II (X is an eliminable group) with a compound of formula III preferably in the presence of a base (e.g. an alkaline metal hydroxide) in a solvent (e.g. acetone) at room temperatures or with heating. The above-mentioned compound of formula I exhibits an depression effect on contraction of the urinary bladder and is useful for improving arrhythmia, congestive heart failure, asthma, Parkinson disease, angina pectoris, etc. The dosage of the compound of formula I is 0.01 to 20mg/ kg/day in the case of intravenous administration, 0.1 to 20mg/kg/day in the case of intramuscular injection or 0.5 to 100mg/kg/day in the case of oral administration.
PURPOSE: To obtain a zirconium based Mo adsorbent having an excellent Mo- adsorbability and Tc-eluting property by constituting the adsorbent of a skeletal structure consisting mainly of repetition unit shown by a specific formula. CONSTITUTION: The Mo-absorbent for&lt;99&gt; Mo-&lt;99m&gt; Tc generator is composed of a skeletal structure consisting mainly of repetition unit shown by formulae I, II, III and IV, wherein X is halogen or a 1 to 6 C alkoxy group and at least 10% of X is halogen; R is 1 to 6 C alkylene or polymethylene, or a carbon chain with an unsaturated bond. The branched structure is controlled by the bonding at any one of the unit of repetition and the content of the repetition unit. The adsorbent is water-insoluble, adsorbs only Mo from an aqueous solution containing Mo, and is capable of eluting&lt;99m&gt; Tc generated from&lt;99&gt; Mo, a radioactive isotope. Thus the Mo adsorbent is used for the preparation of a practical generator, using&lt;99&gt; Mo obtained from a natural Mo.  The adsorbent is obtained by thermally treating a precursor which is available by a chemical reaction between zirconium halide or halogenated zirconium oxide and alcohol.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system that normalizes healthcare data in various formats and exchange the data between those concerned.  &lt;P&gt;SOLUTION: The system comprises a first computer system 10, a second computer system and a rules engine. The first computer system 10 has healthcare data stored therein. The second computer system is in operable communication with, and is configured to extract the healthcare data from the first computer system 10. The rules engine normalizes the extracted healthcare data to a predefined format. The rules engine defines a plurality of healthcare data fields in the predefined format, as well as a plurality of relationships between fields of normalized data.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
1,217,388. 9,10-Ethanoanthracenes. SOC. INDUSTRIELLE POUR LA FABRICATION DES ANTIBIOTIQUES. 30 May, 1968 [8 June, 1967; 6 Sept., 1967], No. 25883/68. Heading C2C. The invention comprises compounds of the Formula (I) and their acid addition and quaternary ammonium-salts wherein R represents a hydrogen atom or a C 1-6  alkyl, C 1-6  hydroxyalkyl, C 2-6  alkoxy carbonyl or C 2-6  hydroxy alkoxyalkyl radical or a radical of the formula -X-Ar, wherein X represents a divalent radical derived from a C 1-6  saturated or unsaturated aliphatic hydrocarbon and Ar represents a phenyl radical which may be substituted by one or more halogen atoms and/or one or more C 1-6  alkyl or C 1-6  alkoxy radicals and their preparation by reacting a 9,10-dibromoanthracene with a 1 -R-substituted-piperazine in the presence of a hydrogen bromide-binding alkaline agent and heating the resulting 9-(1-R-aubstituted - piperazin - 4 - yl) anthracene of the Formula (3) with ethylene under a pressure of at least 30 kg./cm.&lt;SP&gt;2&lt;/SP&gt; in a solvent and where R represents an C 2-6  alkoxycarbonyl radical, hydrolysing said compound to give a compound of the Formula (I) where R represents a hydrogen atom and, if desired, reacting said compound with a halide of the formula Hal-R 1 , where R 1  is the same as R but does not represent a hydrogen atom or an alkoxycarbonyl group and Hal represents a chlorine, bromine or iodine atom and, if desired, converting any resulting compound of the Formula (I) into an acid addition or quaternary ammonium salt thereof. 9 - (1 - R 2  - substituted - piperazin - 1 - yl) anthracenes of the Formula (III) may also be prepared by reacting a 9-bromoanthracene with 1 - R 2  - substituted - piperazin - 4 - yl - lithiums where R 2  has the same meaning as R except that it does not represent a hydrogen atom or a hydroxyalkyl, alkoxycarbonyl or hydroxyalkoxyalkyl radical. Therapeutic compositions with antihistaninic and antianaphylactic properties, for oral, parenteral or topical administration, comprise the compounds of the invention with a carrier.
PROBLEM TO BE SOLVED: To produce a sugar-coated tablet capable of exhibiting a sufficient impact resistance in spite of a low equilibrium relative humidity by carrying out a spraying sugar coating method using a specific talc and a specified crystalline cellulose as a spraying agent. SOLUTION: A spraying sugar coating is carried out by using a spraying agent containing (A) a talc and (B) a crystalline cellulose to produce a sugar- coated tablet having &lt;=60% equilibrium relative humidity. The average particle diameter of the ingredient A is preferably 2-20 μm and the average particle diameter of the ingredient B is preferably 2-80 μm. The amount of the ingredient B is preferably 10-30 wt.% based on the weight of the spraying agent. Vitamins are preferably contained as an active ingredient in the sugar-coated tablet. The resultant sugar-coated tablet has preferably &lt;=60% equilibrium relative humidity, 1-25 wt.% content of the ingredient B in the sugar-coating layer and &gt;=3% friability. Thereby, the sugar-coated table capable of stably including even active ingredients decomposed by the presence of water can be obtained.
The invention relates to a process for preparing a novel influenza vaccine, belonging to the technical field of preparation technology of vaccine. The invention comprises that influenza viruses of A1 and A3 of hypotype and B-type are diluted via virus nutrient solution and are individually inoculated mammal cells which grows to single layer according to 1:10 &lt;-1&gt; -1:10 &lt;-7&gt;, yielding virus liquid which contains the influenza viruses. After being deactivated and purified, each virus primary liquid is obtained. The antigen content of each virus primary liquid is detected. The antigen contents of the virus primary liquids of influenza viruses of A1 and A3 of hypotype and B-type are respectively regulated to prepare the vaccine. The invention has the advantage that by employing the mammal cells to produce the influenza vaccines, the animal immunogenicity experiments of the product show that 15 micrograms of hemagglutinin is capable of enabling serums of all experimental animals to be in seroconversion, and the HI antibody titers are all over 1:40.
An approach for detecting potential medical conditions may be provided. Privacy laws and healthcare regulations may prevent healthcare entities from sharing data or acknowledging even seeing a patient. Secure multi-party computation can allow for the analysis of or more patient&#39;s private health data in a secure database. The private health data will only be visible to the health entity which owns or controls the data. Further, a system with oblivious random access memory may be presented which allows for the analysis of one or more patient&#39;s multiple private healthcare records. A medical condition diagnosis may be made from the analysis of the multiple private healthcare records by the secure multi-party computation using oblivious random access memory, without divulging information any private healthcare data to unauthorized parties.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a neurite extension promoting agent capable of promoting the regeneration of the central nerve.  &lt;P&gt;SOLUTION: The neurite extension promoting agent contains, as an active component, a polypeptide having neurite extension promoting activity such as a polypeptide at least containing CEP-68 protein or its center region. A polypeptide having a neurite extension promoting activity was first found by the invention. The polypeptide has the activity to promote the extension of the neurite of the central nerve. Accordingly, the neurite extension promoting agent is useful for the regeneration of the central nerve.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a radioactive diagnostic and therapeutic agent which contains an ingredient obtained by binding a radioactive nuclide to a found ligand that is bound to lectin existing on the surfaces of tumor cells to exhibit a high accumulation ability on tumors and is useful for diagnosing / treating the tumors.  &lt;P&gt;SOLUTION: This tumor-treating agent contains a glycoprotein having a molecule specifically binding to lectin existing on the surfaces of tumor cells as an active ingredient. The tumor-treating agent preferably contains the glycoprotein wherein the molecule specifically binding to the lectin existing on the surfaces of the tumor cells preferably comprises N-acetylglucosamine or mannose. The tumor-diagnosing agent preferably comprises the glycoprotein radioactively labeled with In-111, Tc-99m, or the like. The tumor-treating agent preferably comprises the glycoprotein radioactively labeled with In-111, I-131, or the like.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention relates to intend shield shell mould YM311593(from a strain&lt;i&gt;Paraconiothyrium&lt;/i&gt;&lt;i&gt;?&lt;/i&gt;Sp.? YM311593) in tunning, separate and obtain a kind of xanthone compounds and application thereof, microorganism belonging to genus technical field of pharmaceuticals. Production bacterial strain YM311593 of the present invention is preserved in Chinese Typical Representative culture collection center on April 10th, 2013, does is deposit number CCTCC? No:? M? 2013142. The present invention is separated and obtains a kind of xanthone compounds through normal fermentation, extraction by bacterial strain YM311593. Activity test confirms that this compound has obvious antitumor cell activity and anti-fungal activity of plant pathogenic, has the antineoplastic new as preparation and the potential use of agricultural antiseptic.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an inserted fused body which comprises a human protein synthesis inhibitor and a human physiologically active substance inserted thereinto to realize a more purposive structure while maintaining the function of each conjugated protein; and a medicine composition containing the inserted fused body as an effective component.  &lt;P&gt;SOLUTION: The inserted fused body having the functions of RNase 1 and bFGF is prepared by inserting a human bFGF, i.e. a human physiologically active substance, into the primary sequence corresponding to the loop position of a human RNase 1, i.e. a human protein synthesis inhibitor, to be expressed in a host cell. The inserted fused body exhibits a cytotoxic activity selectively to a cell highly expressing an FGF receptor of cancer cells, etc.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention discloses a method for controlling the total count of bacteria carried by copepoda. The method comprises the following steps: preparing a Bdellovibrio sp. diluent of which the concentration is 2*10&lt;2&gt;-2*10&lt;5&gt;PFU/mL, and mixing the Bdellovibrio sp. diluent with a mixed solution of sodium glutamate and cane sugar in the volume ratio 1:1 to obtain a Bdellovibrio sp. preparation; and mixing the Bdellovibrio sp. preparation with a pretreated copepoda-containing water sample. The method provided by the invention is simple and feasible, and is suitable for industrial batch production. The contained sodium glutamate and cane sugar do not have toxic or side effects on water bodies and the copepoda, and do not cause pollution to the water bodies or death of beneficial aquatic plankton such as the copepoda. Through the method disclosed by the invention, the total count of the bacteria carried by the copepoda can be effectively controlled within 103cfu/mL in 24 hours, and the regeneration of the bacteria is slowed down for a long period of time.
A spirit shampoo comprises an alkaline compound, a medicinal substance, an alcohol or alcohols, and glycerol and/or oils or fats. The alcohol, which may be methyl alcohol, may be replaced in part by fatty alcohols of the kind produced by the hydrogenation of vegetable oils which are then sulphonated and treated with ethanolamine to produce liquids marketed under the trade name, sulphonated Lorol, Liquid T.A.  The alkaline and medicinal substances may be in the form of ammoniated quinine, and the alkali is not present in sufficient quantity to saponify the fats or oils when present.  When employed, the medicinal substance is stated to be made available in a specially active condition. Water if present is in small quantity.ALSO:A spirit shampoo comprises an alkaline compound, a medicinal substance, an alcohol or alcohols and glycerol and/or oils or fats.  The alcohol, which may be methyl alcohol, may be replaced in part by fatty alcohols of the kind produced by the hydrogenation of vegetable oils which are then sulphonated and treated with triethanolamine to produce liquids marketed under the trade name &#34;Sulphonated Lorol, Liquid T.A.&#34;  The alkaline and medicinal substances may be in the form of ammoniated quinine, the alkali not being present in sufficient quantity to saponify the fats or oils.  When applied to the head the medicinal substance is stated to be made available in a specially active condition. Water if present is in small quantity.
PURPOSE:To provide the titled water-based coating liquid, by adding a sucrose ester and a water-soluble gum to water or an aqueous solution of an alcohol as essential components, and dispersing a specific water-insoluble hydroxycarboxylic acid cellulose derivative powder in the solution. CONSTITUTION:A sucrose ester and a water-soluble gum (e.g. methylcellulose) are dissolved or dispersed as essential components in water or an aqueous solution of an alcohol containing &lt;=20wt% 1-3C lower alcohol. The objective enteric coating liquid is produced by dispersing the powder of a water-insoluble hydrocarboxylic acid cellulose derivative of formula (Glu is glucose anhydride skeleton of cellulose and represented by C6H7O2; R1 is H or 1-5C carboxyalkyl; at least one of R2 and R3 is carboxy, etc. when R1 is H) and having particle diameter of &lt;=100mu (e.g. carboxymethylethylcellulose) in the above solution or dispersion. The obtained liquid is useful as an economical and safe water-based enteric coating liquid.
Peptide-based hydrogels in which the peptides coalesce such that they &#39;self-assemble&#39; to form a hydrogel. Such hydrogels can be used to deliver pharmaceutically active compounds through mucosal tissue. The peptides have 2-20 amino acids. Preferred peptides have 6-10 amino acids (e.g. FEFEFKFK, FEFEFRFR). The peptides have been found to adhere well to mucosal tissue allowing for good delivery of pharmaceutically active compounds and may be used to treat pain, inflammation and infection of the oral cavity (e.g. sore throat).
The present invention provides a novel 3-substituted piperazine triazole alcohol antifungal compound and salts thereof, which relates to the technical field of medicine. A chemical structure general formula of the compound is disclosed in the specification, wherein X stands for hydrogen or methyl; M stands for hydrogen, hydroxy and an ester group; Y stands for a 2, 4-difluorin group; and R stands for heterocyclic formyl or heterocyclic acetyl, substituted heterocyclic formyl or substituted heterocyclic acetyl, heterocyclic methyl or substituted heterocyclic methyl, heterocyclic methoxyphenyl or substituted heterocyclic methoxyphenyl and 3&#39;, 4&#39;-heterocycle dense benzyloxyphenyl. Substituted groups comprise an aliphatic chain of 1 to 4 carbon atoms, such as methyl, ethyl, trifluoromethyl, hydroxymethyl, methoxymethyl, ethoxymethyl, isopropyl and tertiary butyl, halogen, such as F, Cl, Br and I, and electron-withdrawing groups or electron-donating groups, such as nitryl, a nitrile group, carbamyl, N-methyl carbamyl, N-ethyl carbamyl, N, N-dimethylcarbamyl, N, N-diethylcarbamyl, methoxy acyl, ethoxyacyl, amino, methylamino, acetylamino, hydroxy, a methoxy group and an ethoxyl. The Substituted groups can be on every positions of the heterocycle, and can be used as a single substituted mode and a multiple substituted mode. The compound can be made into salt by matching with various kinds of inorganic acid and organic acid. The 3-substituted piperazine triazole alcohol antifungal compound and salts thereof have strong antifungal activity, and can be used for preparing antifungal medicaments.
Patients who met the inclusion criteria and were admitted for posterior maxilla rehabilitation participated in this prospective, randomized, controlled clinical trial. The three methods used to lift the sinuses were randomized: piezosurgery using a surgical guide, a drill specifically made for lateral sinus lift, and traditional drills. Recorded were the duration of the procedure, accessibility, and intraoperative complications. During the first week following surgery, analgesic intake and pain using a visual analog scale (VAS) were assessed assessed. Preoperatively and on the second and seventh postoperative days, edema was assessed. Preoperatively and on the seventh postoperative day, the patient\&#39;s quality of life using the OHIP-14 questionnaire, experiences, and expectations were evaluated.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide health food preventing excess ingestion of cadmium and exhibiting antitumor ability, and to provide a method for easily producing the health food at a low cost.  &lt;P&gt;SOLUTION: The anti-tumor health food has as the raw material the carpophore of Agaricus blazei Murrill containing cadmium and ≥5 pts.wt. of free cyanogen based on 100 pts.wt. of the cadmium. The method for producing the anti-tumor health food as a final product containing ≥5 pts.wt. of the free cyanogen based on 100 pts.wt. of the cadmium as inevitable impurities comprises including a process of extracting in hot water nonfermentable carpophore of Agaricus blazei Murrill and using Agaricus blazei Murrill dry carpophore having cadmium concentration of ≤20 ppm.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Proposed method rejuvenation consists in intravenous injection of a new bacterial collagenolytic agent to replace aged collagen to young more permeable collagen in entire organism with renewal the young condition for the cells&#39; functions. Collagen - the principal protein of connective tissue is extra-cellular. With aging collagen becomes denser and its permeability decreases. The replacement of old collagen to young collagen by proposed method results in acceleration of interstitial fluid circulation in connective tissue. It improves the supply of the cells with nutrients, hormones and other biological active compounds and removal of metabolism products. Events involved therewith may be defined as the rejuvenation.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to sports medicine, and can be used for weight reduction in obesity patients. Dynamic load is a complex of physical exercises, which makes 40 hours of training, each training including 20–30 minutes of cardioplasty and 30–40 minutes of power load. Training sessions are three times a week. Each feeding stage makes one month. In the first month, daily food intake makes 100 g of complex carbohydrates, 100 g of proteins, and 30 g of fats for one meal, and the drinking regime makes at least 2 litres of water a day. During the second month, carbohydrate content is reduced weekly. During the third month, protein-carbohydrate alternation of food is performed during the first week, not exceeding 1100 kcal a day, and during the second and third weeks of the third month, the menu, multiplicity and weight of the first month&#39;s food intake are stored. During the second and third weeks of the month, calculating the number of kilocalories in relation to human growth, and in the fourth week of the third month, consumption of carbohydrates is excluded and additionally water consumption is reduced to 2 litres a day. On the last day of the week one consumes not more than 1 litre of water a day. First week of the second month consumes 100 g of carbohydrates in the permitted products during the day, the second week - 90 g of carbohydrates during the day, third - 80 g of carbohydrates during the day and fourth - 70 g of carbohydrates during the day. Ratio of the consumption of kilocalories to the human growth is 1000 kcal to 160 cm; with growth of 160 cm to 170 cm - 1200 kcal; with growth from 170 to 180 cm - 1400 kcal and with growth above 180 cm - 1600 kcal.EFFECT: method provides higher availability and convenience of method implementation for program participants due to alternation and balance of power supply stages.3 cl, 3 ex, 3 dwg
PURPOSE:To obtain the subject dental material maintaining a given color tone free from yellowing phenomena even by after soldering with gold solder, containing a specific amount of antimony trioxide as a yellowing inhibitor, by baking and calcining a dental ceramic material on metallic surface especially containing silver and repeatedly calcining under the condition. CONSTITUTION:A dental ceramic material containing 0.1-2.0wt.%, especially 1.0wt.% antimony trioxide (Sb2O3) as a yellowing inhibitor. The particle diameter of Sb2O3 powder is about 5-10mum. The blending is carried out by a ball mill. As an another method, 0.1-2wt.% Sb2O3 may be added to glass frit when silica, alumina and alkali carbonate are melted to give the glass frit. Glass frit blended with Sb2O3 is heat-treated at &gt;=the softening point (usually 900 deg.C), crystallized, ground into &gt;=about 20mum, deposited or a metallic material, repeatedly calcined and used.